Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Prevention Drugs Will Be Addressed In FDA Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Metabolic syndrome may also be discussed in draft document expected to be out by year-end.

You may also be interested in...



Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines

Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.

Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines

Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.

FDA Preventative Drugs Guidance Will Address Trial Design, Biomarkers

Agency will host a workshop with DIA in the spring to explore new scientific strategies for developing preventative therapies, FDA's Gottlieb says.

Related Content

Topics

UsernamePublicRestriction

Register

PS064656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel